Biopharmaceuticals : (Record no. 129067)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04458cam a2200505Ki 4500 |
| 001 - CONTROL NUMBER | |
| control field | 9781351013154 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | FlBoTFG |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20220509193046.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS--GENERAL INFORMATION | |
| fixed length control field | m o d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu---unuuu |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201211s2021 flu ob 001 0 eng |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | OCoLC-P |
| Language of cataloging | eng |
| Description conventions | rda |
| Transcribing agency | OCoLC-P |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781351013154 |
| -- | electronic book bk |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 1351013157 |
| -- | electronic book bk |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781351013130 |
| -- | (electronic bk. : EPUB) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 1351013130 |
| -- | (electronic bk. : EPUB) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781351013147 |
| -- | (electronic bk. : PDF) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 1351013149 |
| -- | (electronic bk. : PDF) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781351013123 |
| -- | (electronic bk. : Mobipocket) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 1351013122 |
| -- | (electronic bk. : Mobipocket) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Cancelled/invalid ISBN | 9780815347774 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Cancelled/invalid ISBN | 0815347774 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1227044579 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC-P)1227044579 |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RM301.4 |
| Item number | .B44 2021 |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED |
| Subject category code subdivision | 008000 |
| Source | bisacsh |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED |
| Subject category code subdivision | 071000 |
| Source | bisacsh |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | TDCW |
| Source | bicssc |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.7 |
| Edition number | 23 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Behera, Basanta Kumara, |
| Relator term | author. |
| 245 10 - TITLE STATEMENT | |
| Title | Biopharmaceuticals : |
| Remainder of title | challenges and opportunities / |
| Statement of responsibility, etc | authored by Basanta Kumara Behera. |
| 264 #1 - | |
| -- | Boca Raton : |
| -- | CRC Press, |
| -- | 2021. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource : |
| Other physical details | illustrations |
| 336 ## - | |
| -- | text |
| -- | txt |
| -- | rdacontent |
| 337 ## - | |
| -- | computer |
| -- | c |
| -- | rdamedia |
| 338 ## - | |
| -- | online resource |
| -- | cr |
| -- | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Biopharmaceutical : A New Confront -- Biopharmaceutical Production -- Transitioning from Pharmaceutical to Biopharmaceutical -- Biopharmaceutical from Animal cells -- Plant Biomolecules and Therapeutic -- Biosimilar -- Biopharmaceutical Supply Chain Management. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | "This book highlights how traditional microbial process technology has been upgraded for the production of biologic drugs, and evolution of manufacturing process to meet the global market demand with quality products under the guide lines of internally recognised regulatory bodies. This piece of work also carries information on how armed with deeper understanding of life threatening disease, the biopharmaceutical companies or life sciences industries have developed royal scientific heritage of understanding by developing formal and informal partnerships with researchers in institute, universities and other R&D organisation to fulfil the promise of timely quality production with perfect safety and security. One of the most interesting aspects of this piece of work is the conceptual development of personalized medicine (or precision medicine) to get the right treatment to the right patient at the right dose at the earlier stage of development of any inherited disease. Besides this, it also high lights on the most challenging aspects of modern biopharmaceutical science focusing on the most burning topics like design and development of biologic drugs; use of diversified groups of host cells belonging from animals, plants, microbes, insects and mammals; stem cell therapy and gene therapy; supply chain management of biopharmaceuticals; and the future scope of biopharmaceutical industry development. This book is a latest resource for a wide circle of scientists, students and researchers involve in understanding and implementing the knowledge of biopharmaceutical to develop biologics for life saving drugs, and bring awareness on personalized medicines that can potentially offer patients faster diagnoses, fewer side effects and better outcomes. Features: Explains how the traditional cells culture methodology has been changed to fully continuous or partially continuous process. It explains how to design and fabricate living organs of body by 3D bioprinting technology. It focuses on how a biopharmaceutical company confront with various problems of regulatory bodies, and develop innovative biologic drugs. It narrates in detail the update information on stem cell therapy and gene therapy. It explains the development strategies and clinical significance of bio-similars and bio-betters. It high lights on supply chain management of biopharmaceuticals"-- |
| 588 ## - | |
| -- | OCLC-licensed vendor bibliographic record. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Pharmaceutical biotechnology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Biopharmaceutics. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | MEDICAL / Biochemistry |
| Source of heading or term | bisacsh |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | MEDICAL / Pharmacology |
| Source of heading or term | bisacsh |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Materials specified | Taylor & Francis |
| Uniform Resource Identifier | https://www.taylorfrancis.com/books/9781351013154 |
| 856 42 - ELECTRONIC LOCATION AND ACCESS | |
| Materials specified | OCLC metadata license agreement |
| Uniform Resource Identifier | http://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf |
No items available.